Benefits of REPRIEVE to Minimize Risk

All participants will receive guidance on steps to improve heart health, including:

- Taking antiretroviral therapy
- Keeping cholesterol, blood pressure, and blood sugar in good range
- Not smoking
- Eating well
- Exercising

Getting to the Heart of HIV

Call: 1-877-29-HEART
www.reprievetrial.org
Men and women with HIV are 50–100% more likely to develop heart disease. The REPRIEVE clinical research trial may help people get in front of this problem.

What is REPRIEVE?

REPRIEVE is a clinical research trial testing whether a daily dose of a statin medication (pitavastatin) lowers the risk of heart-related disease among people living with HIV.

- **LENGTH OF PARTICIPATION**: 48 months on average
- **SIMPLE TIME COMMITMENT**: Visits about 3 times per year
- **THERE’S A SITE NEAR YOU**

To learn more about the trial and find a site near you, visit us at www.reprievetrial.org

Am I eligible?

- HIV-positive between ages 40 and 75
- On antiretroviral therapy (ART) for at least 6 months prior to study entry
- No history of cardiovascular disease (including heart attack or stroke)
- Not currently using a statin drug

Why should I participate?

By participating in REPRIEVE, you will be:

- Helping us understand whether pitavastatin prevents heart-related disease and other chronic complications among people living with HIV!
- Pay it forward, help to make it possible for people with HIV to live longer and healthier lives.

Pitavastatin is a medication approved for treatment of high cholesterol. In the REPRIEVE trial, we will test whether pitavastatin can prevent heart disease in HIV.

Learn more about the REPRIEVE trial and how to sign up!

www.reprievetrial.org